SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is trending following a decline in share price, as investors weigh the company's upcoming FDA filing for sonelokimab against concerns over intense competition in the hidradenitis suppurativa market and mixed sentiment regarding clinical data readouts. While some traders express frustration with management's communication and the stock's recent performance, others maintain a bullish long-term thesis based on the potential of sonelokimab as a best-in-class treatment and a strong cash position.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

Sellas Life Sciences shares are trending due to a significant sell-off driven by community-driven speculation and uncertainty regarding the status of the Phase 3 REGAL trial, as investors react to circulating third-party survival models and the lack of official updates during a self-imposed quiet period. While many shareholders view the decline as orchestrated market manipulation and an opportunity to accumulate shares, others are expressing concern over the delay in reaching the trial's 80th event.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers Health is currently experiencing high volatility driven by speculation regarding potential peptide product launches and broader global expansion, alongside community debate over short interest and institutional activity. Investors remain divided, with some highlighting the company's long-term growth potential and data-driven platform, while others focus on regulatory risks and intense fluctuations in trading volume.

Oklo, Inc. engages in the development of fission reactors. It provides clean energy through the design and deployment of fast fission power plants. The company was founded by Jacob DeWitte and Caroline Cochran on July 3, 2013 and is headquartered in Santa Clara, CA.

Oklo Inc. - Ordinary Shares - Class A

Oklo Inc.

Oklo is trending due to investor backlash following the launch of a new $1 billion at-the-market equity offering program, which has sparked significant concerns regarding shareholder dilution and insider selling. While some traders view the price decline as a buying opportunity based on long-term nuclear energy demand, others are heavily bearish, citing the lack of commercial revenue and the company's reliance on repeated capital raises.

NuScale Power Corp. provides proprietary and innovative advanced small modular reactor (SMR) nuclear technology, with a mission to help power the global energy transition by delivering safe, scalable, and reliable carbon-free energy. Its products include VOYGR SMR Plants and Energy Exploration (E2) Centers. The company was founded by José N. Reyes in 2007 and is headquartered in Corvallis, OR.

NuScale Power Corporation - Ordinary Shares - Class A

NuScale Power Corp

NuScale Power is trading lower following a downgrade by UBS, which cited concerns regarding a lengthy project build timeline, limited customer commitments, and projected future cash burn. While retail traders continue to debate the company's long-term commercial execution and project viability, many market participants view the pullback as an overreaction to analyst sentiment rather than a fundamental change in the sector's nuclear power thesis.

Amplify Commodity Trust - Breakwave Tanker Shipping ETF

Breakwave Tanker Shipping ETF

Breakwave Tanker Shipping ETF is trending as traders react to its significant year-to-date gains and ongoing geopolitical instability in the Middle East, particularly around the Strait of Hormuz. Community discussion centers on the potential for continued upside driven by shipping rate volatility and the scarcity of tanker capacity, alongside debate regarding the risks of entering the trade at current parabolic price levels.

Onyx is an infrastructure for a multi-asset, scalable, and cryptographically secure ledger. Onyx functions as a blockchain-based technology that enhances financial ecosystems by enabling a more efficient and interconnected economy, with a mission to develop cryptographic ledgers that optimize security, scalability, and usability. XCN is native to the Onyx XCN Ledger Blockchain as well as the Onyx Goliath Blockchain. XCN is also used as an ERC-20 token for Staking and Governance.

Onyxcoin

The conversation surrounding Onyxcoin is heavily polarized, with many traders labeling the asset a "pump and dump" scheme due to consistent price volatility and skepticism regarding its leadership. Conversely, some community members remain bullish, focusing on technical developments like the Onyx Mesh infrastructure, ongoing staking rewards, and potential institutional adoption through the integration of Chain's technology.

Select Sector SPDR Trust (The) - State Street Energy Select Sector SPDR ETF

Energy Select Sector SPDR Fund

The Energy Select Sector SPDR Fund is trending primarily due to ongoing geopolitical tensions in the Middle East, specifically reports of strikes affecting oil infrastructure and concerns over the security of the Strait of Hormuz. Traders are closely monitoring the impact of these disruptions on global oil supply and refining margins, leading to polarized discussions and continued volatility in the sector.

Listed Funds Trust - Roundhill Magnificent Seven ETF

Roundhill Magnificent Seven ETF

The Roundhill Magnificent Seven ETF is trending as traders closely monitor a rotation out of mega-cap tech into broader market sectors, fueled by concerns over stretched AI valuations and cooling investor appetite for the group. While some market participants express frustration over the underperformance of these names, others are debating whether current price levels represent a structural re-rating or an attractive buying opportunity for long-term investors.

Circle Internet Group, Inc. is a financial technology company that enables businesses of all sizes to harness the power of digital currencies and public blockchains for payments, commerce and financial applications worldwide. The company was founded by Jeremy J. Allaire and Patrick Sean Neville in August 2013 and is headquartered in New York, NY.

Circle Internet Group Inc. - Ordinary Shares - Class A

Circle

The stock is trending due to speculative momentum and increased volatility surrounding the upcoming Clarity Act vote, with traders debating whether potential regulatory clarity will drive institutional adoption of stablecoins or if increasing competition from major banks will compress margins. Community sentiment remains polarized, with bulls pointing to the company's expanding infrastructure and institutional partnerships, while bears warn of valuation concerns and the threat of bank-led stablecoin alternatives.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Lakewood-Amedex Biotherapeutics to Present at H.C. Wainwright 28th Annual Global Investment Conference

Lakewood-Amedex Biotherapeutics to Present at H.C. Wainwright 28th Annual Global Investment Conference Lakewood-Amedex Biotherapeutics to Present at H.C. Wainwright 28th Annual Global Investment Conference PR Newswire SARASOTA, Fla., Sept. 8, 2026 SARASOTA, Fla., Sept. 8, 2026 /PRNewswire...

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

Gainers

bioAffinity Technologies (NASDAQ:BIAF) shares increased by 68.4% to $7.68 during Tuesday's pre-market session. The market value of their outstanding shares is at $2.7 million.
Lakewood-Amedex (NASDAQ:LABT)read more...

12 Health Care Stocks Moving In Monday's After-Market Session

Gainers

Lakewood-Amedex (NASDAQ:LABT) stock rose 38.0% to $3.45 during Monday's after-market session. The company's market cap stands at $5.4 million.
Alamar Biosciences (NASDAQ:ALMR) stock rose 7.4% to $32.8.read more...

12 Health Care Stocks Moving In Wednesday's Intraday Session

Gainers

Advanced Biomed (NASDAQ:ADVB) shares moved upwards by 108.6% to $14.77 during Wednesday's regular session. The company's market cap stands at $11.5 million.
Lakewood-Amedex (NASDAQ:LABT) shares movedread more...

Antibiotic Resistance Crisis Drives Spotlight to Lakewood-Amedex Biotherapeutics and Its Phase 2-Ready Antimicrobial Candidate

As antimicrobial resistance (AMR) continues to rank among the world's most urgent public health challenges, Lakewood-Amedex Biotherapeutics (NASDAQ:LABT) is highlighting new laboratory data supporting the potential of its lead drug candidate, Nu-3, following renewed national attention on combating drug-resistant infections. The company's announcement comes after the Presidential Advisory Council on Combating Antibiotic-Resistant Bacteria (PACCARB) discussed priorities for the next five-year National Action Plan designed to strengthen the U.S. response to antimicrobial resistance.

Lakewood-Amedex Biotherapeutics Highlights Nu-3 Resistance Data in Response to National Action Plan of Presidential Advisory Council on Combating Antibiotic Resistant Bacteria

Lakewood-Amedex Biotherapeutics Highlights Nu-3 Resistance Data in Response to National Action Plan of Presidential Advisory Council on Combating Antibiotic Resistant Bacteria Lakewood-Amedex Biotherapeutics Highlights Nu-3 Resistance Data in Response to National Action Plan of Presidential...

Lakewood-Amedex Biotherapeutics Announces Preclinical Safety Data Supporting Clinical Dose Selection for Upcoming Phase 2a Trial of Nu-3 Gel

Lakewood-Amedex Biotherapeutics Announces Preclinical Safety Data Supporting Clinical Dose Selection for Upcoming Phase 2a Trial of Nu-3 Gel Lakewood-Amedex Biotherapeutics Announces Preclinical Safety Data Supporting Clinical Dose Selection for Upcoming Phase 2a Trial of Nu-3 Gel PR Newswire...

Lakewood-Amedex Biotherapeutics Supports Reintroduction of the PASTEUR Act and Focus on Combating Antimicrobial Resistance

Lakewood-Amedex Biotherapeutics Supports Reintroduction of the PASTEUR Act and Focus on Combating Antimicrobial Resistance Lakewood-Amedex Biotherapeutics Supports Reintroduction of the PASTEUR Act and Focus on Combating Antimicrobial Resistance PR Newswire SARASOTA, Fla., July 7, 2026 Company...

Lakewood-Amedex Biotherapeutics Announces World-Renowned Expert David G. Armstrong, M.D., Ph.D., as Study Chair for Phase 2a Trial of Nu-3 in Infected Diabetic Foot Ulcers

Lakewood-Amedex Biotherapeutics Announces World-Renowned Expert David G. Armstrong, M.D., Ph.D., as Study Chair for Phase 2a Trial of Nu-3 in Infected Diabetic Foot Ulcers Lakewood-Amedex Biotherapeutics Announces World-Renowned Expert David G. Armstrong, M.D., Ph.D., as Study Chair for Phase 2a...

Lakewood-Amedex Biotherapeutics Secures Composition of Matter Patent Protecting New Bisphosphocin Compounds Being Developed for High-Need Antimicrobial Infections

Lakewood-Amedex Biotherapeutics Secures Composition of Matter Patent Protecting New Bisphosphocin Compounds Being Developed for High-Need Antimicrobial Infections Lakewood-Amedex Biotherapeutics Secures Composition of Matter Patent Protecting New Bisphosphocin Compounds Being Developed for...

Lakewood-Amedex Biotherapeutics, Inc. engages in the development of novel antimicrobial therapies. Its anti-infective products targeted certain viral diseases like avian influenza, Epstein Barr Virus (EBV), and hepatitis B and C. The company was founded by Roderic Dale on July 11, 2006 and is headquartered in Bradenton, FL.

Lakewood-Amedex Biotherapeutics Inc.

This Newly Listed Biotech Is Soaring – Retail Says $14 Is The Line In The Sand

Equity

Bullish Sentiment

President Trump has promised to issue a $5,000 "dividend" check to every adult American citizen if the Republican Party wins control of both the House and the Senate in the upcoming midterm elections, though the proposal would require congressional approval and follows his earlier $2,000 tariff-dividend plan, which stalled after the Supreme Court struck down much of his tariff authority. Do you think the $5,000 dividend check actually happens? Vote and explain your reasoning in the comments.

Trump has pledged a $5,000 &quot;dividend&quot; check to every adult American citizen if Republicans win control of both the House and Senate in the midterms. Do you think it actually happens?

Stocktwits

Trump has pledged a $5,000 "dividend" check to every adult American citizen if Republicans win control of both the House and Senate in the midterms. Do you think it actually happens?

Current Price	$2.22
Prev Close	$2.05
Open	$2.11
Dividend Yield	N/A
50-Day Moving Average	$2.32
Beta	-0.44
Avg. Volume	781,236.95
PE Ratio	-0.21

52-Week High	$98.20
52-Week Low	$1.66
Market Capitalization	$4.86M
EPS (Annual)	-$8.40
Price to Book	1.11
Revenue Per Employee	$0.00

Feed

News

Sentiment

Fundamentals

Info

LABT Fundamentals